Tin Mesoporphyrin IX (chloride): A Potent Heme Oxygenase Inhibitor for Metabolic and Virological Research

Executive Summary: Tin Mesoporphyrin IX (chloride) is a competitive inhibitor of heme oxygenase (HO) with a Ki of 14 nM, demonstrating high potency in vitro and in vivo (APExBIO C5606). It effectively suppresses hepatic, renal, and splenic HO activity at 1 pmol/kg in animal models, leading to sustained reductions in serum bilirubin (APExBIO). The compound is widely used to investigate heme metabolism, metabolic diseases, and HO-1-mediated signaling in contexts ranging from insulin resistance to viral pathogenesis (Koyaweda et al., 2026). Its crystalline form, molecular weight (754.3), and solubility parameters are rigorously specified. No clinical trials have been reported; use is confined to preclinical and research applications.

Biological Rationale

Heme oxygenase (HO) catalyzes the degradation of heme to biliverdin, releasing ferrous iron and carbon monoxide as byproducts (Koyaweda et al., 2026). HO-1, the inducible isoform, is a critical regulator of oxidative stress and cellular antioxidant responses. Aberrant HO activity is implicated in metabolic diseases, insulin resistance, and metaflammation by modulating intracellular reactive oxygen species (ROS) and redox signaling. In viral pathogenesis, HO-1 upregulation can alter viral replication and morphogenesis, as demonstrated for hepatitis B virus (HBV) (Koyaweda et al., 2026). Selective inhibition of HO activity provides a tractable approach to dissect heme catabolism, study disease mechanisms, and evaluate therapeutic strategies in preclinical models.

Mechanism of Action of Tin Mesoporphyrin IX (chloride)

Tin Mesoporphyrin IX (chloride) is a synthetic metalloporphyrin that binds competitively to the active site of HO enzymes, displacing heme and preventing its catabolism. The compound exhibits a Ki of 14 nM for HO, indicating high-affinity, nanomolar-range inhibition (FezolinetantCatalog). Upon administration in vivo (1 pmol/kg), Tin Mesoporphyrin IX (chloride) inhibits HO activity in hepatic, renal, and splenic tissues for extended durations. This suppression leads to increased heme substrate levels, reduced biliverdin and bilirubin production, and altered heme saturation of hepatic tryptophan pyrrolase. By modulating HO-1 activity, the inhibitor indirectly impacts ROS levels, redox signaling, and downstream metabolic or virological pathways (Koyaweda et al., 2026).

Evidence & Benchmarks

• Tin Mesoporphyrin IX (chloride) inhibits HO activity in vitro with a Ki of 14 nM, outperforming non-metal porphyrins (APExBIO).
• In animal models, a single dose (1 pmol/kg) suppresses hepatic, renal, and splenic HO activity for >24 hours (APExBIO).
• Administration reduces serum bilirubin levels in neonatal hyperbilirubinemia models, confirming in vivo pharmacodynamic activity (APExBIO).
• HO-1 inhibition by Tin Mesoporphyrin IX modulates intracellular ROS and impairs HBV morphogenesis, as shown by decreased viral cccDNA and antigen output (Koyaweda et al., 2026).
• Chemical properties: crystalline solid, molecular weight 754.3, formula C34H34Cl2N4O4Sn·2H, solubility 0.5 mg/ml in DMSO and 1 mg/ml in DMF; stable at -20°C (APExBIO).

This article extends on the mechanistic perspectives presented in Strategic Heme Oxygenase Inhibition in Precision Medicine by providing quantitative in vivo benchmarks and practical workflow guidance for Tin Mesoporphyrin IX (chloride) users.

Applications, Limits & Misconceptions

Tin Mesoporphyrin IX (chloride) is primarily used in preclinical and biochemical research. Applications include:

• Dissecting heme catabolism and HO-1 signaling in metabolic disease and metaflammation models (Advanced Insights into HO Inhibition).
• HO activity assays in liver, kidney, and spleen tissues.
• Studying insulin resistance and metabolic pathway alterations by modulating HO-1 activity.
• Investigating the role of HO-1 in viral replication and morphogenesis, notably in HBV research (Koyaweda et al., 2026).

This article clarifies technical use cases and updates earlier overviews such as Advanced Insights for Heme Oxygenase Research by highlighting recent virological evidence and optimized parameter guidelines.

Common Pitfalls or Misconceptions

• Not a clinical therapeutic: No clinical trials have been conducted; use is limited to animal and cell experiments (APExBIO).
• Non-selectivity between HO isoforms: While potent, most studies do not distinguish HO-1 from HO-2 inhibition unless isoform-specific assays are used (FezolinetantCatalog).
• Solubility and stability constraints: Solutions must be freshly prepared and stored at -20°C for short durations; precipitation and degradation occur above solubility limits or at ambient temperature (APExBIO).
• No effect on non-heme oxygenase pathways: The inhibitor does not block unrelated redox or cytochrome P450 enzymes at tested concentrations (Strategic Heme Oxygenase Inhibition).
• Not suitable for chronic or systemic human administration: Toxicological and pharmacokinetic profiles are not established for clinical use.

Workflow Integration & Parameters

Experimental Design: For HO activity assays, Tin Mesoporphyrin IX (chloride) is typically used at 10–100 nM in vitro or at 1 pmol/kg in animal models. Stock solutions are prepared at 0.5 mg/ml in DMSO or 1 mg/ml in DMF. Solutions should be aliquoted and stored at -20°C; working solutions are stable up to 24 hours at 4°C. For metabolic disease and viral studies, administration regimens are tailored to the experimental endpoint and tissue type. The compound is compatible with standard colorimetric, fluorometric, or LC-MS readouts for heme catabolism.

Comparison with Other Inhibitors: Tin Mesoporphyrin IX (chloride) offers higher HO affinity and in vivo stability than non-tin metalloporphyrins. It is considered a benchmark standard for reproducible inhibition across diverse research settings (FezolinetantCatalog).

For further technical protocols and strategic guidance on integrating Tin Mesoporphyrin IX (chloride) into metabolic or viral research pipelines, see Unlocking the Therapeutic Promise of HO Inhibition, which adds translational and future-oriented perspectives not covered in this procedural dossier.

Conclusion & Outlook

Tin Mesoporphyrin IX (chloride) is a validated, potent, and competitive inhibitor of heme oxygenase activity. Its robust inhibition profile, well-characterized pharmacodynamics, and chemical stability make it a cornerstone reagent for metabolic, virological, and redox biology research. While not approved for clinical use, it has enabled advances in understanding HO-1 signaling, metabolic disease progression, and virus–host interactions. Ongoing research is expected to further refine its application spectrum, including combinatorial strategies in metabolic and infectious disease models. For detailed specifications and ordering, refer to the APExBIO C5606 product page.